A Mount Sinai researcher discovered that many patients with cholangiocarcinoma exhibit a highly elevated expression of B7-H4, a transmembrane protein that inhibits T cell immunity. This could offer a new immunotherapy target for bile duct cancer, a rare disease where breakthroughs are equally rare.